Investor directory

ARCH Venture Partners

ARCH Venture Partners, L.P. is a private equity and venture capital firm founded in 1986 and based in Chicago, Illinois, with additional offices across North America and South America. The firm specializes in early-stage and growth capital investments, primarily focusing on life sciences and biotechnology, but also covering a wide array of technology sectors such as advanced materials, communications technologies, and information technology. ARCH is recognized for its role in commercializing innovations developed at academic research institutions and national laboratories. It has raised over $3 billion through ten venture funds and has invested in more than 150 companies, often co-founding them with leading scientists and entrepreneurs. The firm typically invests between $50,000 and $150 million per company, aiming to enter at seed rounds to minimize risk, and seeks a seat on the Board of Directors for its portfolio companies. While primarily investing in the United States, ARCH also targets opportunities in Canada, Europe, and select countries in Asia, focusing on underserved geographic markets rich in scientific research and technological talent.

Focus

TherapeuticsSeries AScale StageEarly VentureSeries BShow more
http://www.archventure.com
https://crunchbase.com/organization/arch-venture-partners
https://linkedin.com/company/arch-venture-partners
https://signal.nfx.com/firms/arch-venture-partners
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=18847
https://www.privateequityinternational.com/database/#/profile?id=6376
8755 W. Higgins Rd., Suite 1025 Chicago, IL 60631
999 Third Ave., Suite 3400 Seattle, WA 98104
1700 Owens St., Suite 535 San Francisco, CA 94158
5001 Plaza on the Lake Blvd., Suite 103 Austin, TX 78746

Paul Berns

Managing Director

Reetika Bhardwaj

Associate

Kristina M. Burow

Managing Director

Clinton Bybee

Co-Founder and Managing Director

Keith L. Crandell

Co-Founder and Managing Director

David Cruikshank

Partner

SU Fu

Senior Associate

George S. Golumbeski

Venture Partner

Edgar Hotard

Venture Partner

Sean Kendall

Principal

Jay Kocherlakota

Senior Associate

Jay Markowitz

Senior Partner

Mark McDonnell

Managing Director, CFO and CAO

Peter Mintun

Associate

Robert T. Nelsen

Co-Founder and Managing Director

Ari Nowacek

Principal

Corey Ritter

Principal

Carol Suh

Partner

Paul Thurk

Managing Director

Past deals in Therapeutics

Myeloid Therapeutics

Series A in 2023
Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyte approach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.

OncoResponse

Venture Round in 2023
OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.

Remix Therapeutics

Series B in 2022
Remix Therapeutics Inc. engages in the biotech research and development business. It discovers and develops various novel therapeutic RNA processing modulators to target various undruggable disease drivers. The company also offers biology platform to identify and prioritize targets with therapeutically-tractable intervention points in RNA processing. Its REMseq platform validates targets and chemical matter discovery and optimization. The company was founded in 2018 and is based in Cambridge, Massachusetts.

Be Biopharma

Series B in 2022
Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells within the immune system. The company aims to address significant limitations associated with existing cell and gene therapies, such as the challenges of administering multiple doses, unpredictable patient reactions, and the necessity of potentially harmful chemotherapy regimens prior to treatment. Be Biopharma's approach allows for the creation of durable therapies that can be re-administered without toxic conditioning, making these treatments suitable for a range of diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020, Be Biopharma is headquartered in Cambridge, Massachusetts.

LifeMine Therapeutics

Series C in 2022
LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

Nutcracker Therapeutics

Series C in 2022
Nutcracker Therapeutics, Inc. is a biotechnology company focused on developing mRNA therapeutics using a proprietary microfluidic platform. Established in 2017 and based in Emeryville, California, the company specializes in a fully integrated system that allows for the on-demand production of mRNA therapeutics through its ACORN platform. This innovative, computer-controlled RNA manufacturing system utilizes a nucleic acid sequence to produce optimized, nanoparticle-encapsulated RNA therapeutics on single-use biochips. Nutcracker Therapeutics aims to enhance the scalability and efficiency of mRNA production, enabling healthcare companies to create complex multimodal therapeutics at the point of care. By combining advances in RNA biology with semiconductor manufacturing techniques, the company seeks to streamline the discovery, development, and manufacturing processes for mRNA therapies and vaccines.

Transcenta

Post in 2021
Transcenta Holding Ltd. is a clinical-stage biotherapeutics company specializing in the research, development, and manufacturing of antibody-based therapeutics. Founded in 2019 and headquartered in Suzhou, China, Transcenta has additional facilities in major cities including Shanghai, Hangzhou, and Beijing, as well as in Waltham, Massachusetts, and Princeton, New Jersey. The company was formed through the merger of HJB and MabSpace Biosciences and focuses on developing innovative antibodies aimed at treating various conditions. Currently, Transcenta is advancing nine therapeutic antibody molecules targeting oncology and select non-oncology indications, including bone and kidney disorders.

Generate Biomedicines

Series B in 2021
Generate Biomedicines, Inc. develops a platform to invent novel antibodies, peptides, enzymes, receptors, and other therapeutic proteins. It offers Generative Biology, a machine learning based solution that learns from all known proteins in order to encode and apply the fundamental principles of how genetic sequences lead to protein structure and function for creating novel protein sequences with optimized therapeutic potential. Its Generative Biology is applied to all protein modalities and generate novel proteins with desired functions and solutions that interact potently and specifically with therapeutic targets. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in March 2020. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

ROME Therapeutics

Series B in 2021
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.

ImmuneID

Series A in 2021
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.

Interline Therapeutics

Series A in 2021
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities. It uses genomics, proteomics, structural biology, and computational chemistry to map and modulate protein communities. Interline leverages recent advancements in these technologies, as well as collaborations with leading academic groups, to develop a precision medicine platform focused on three essential areas, genomics, communities, and modulators. The South San Francisco, California-located company was founded by Zach Sweeney in 2020.

Jaguar Gene Therapy

Series B in 2021
Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases.

Volastra Therapeutics

Seed Round in 2021
Volastra Therapeutics, Inc., a biotechnology company, develops therapies for the treatment of metastatic cancers. The company offers a library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. Volastra Therapeutics, Inc. was incorporated in 2019 and is based in New York, New York.

OncoResponse

Series C in 2021
OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.

Interline Therapeutics

Seed Round in 2021
Interline Therapeutics is a drug discovery platform that enables the company to map and correct dysfunctional protein communities. It uses genomics, proteomics, structural biology, and computational chemistry to map and modulate protein communities. Interline leverages recent advancements in these technologies, as well as collaborations with leading academic groups, to develop a precision medicine platform focused on three essential areas, genomics, communities, and modulators. The South San Francisco, California-located company was founded by Zach Sweeney in 2020.

ImmuneID

Venture Round in 2021
ImmuneID is a precision immunology company using its proprietary platform to simultaneously identify and therapeutically target millions of antibody interactions that drive immune diseases.

Excision BioTherapeutics

Series A in 2021
Excision BioTherapeutics Inc. is a life science company founded in 2015 and based in Philadelphia, Pennsylvania, dedicated to developing gene editing therapeutics for life-threatening diseases caused by neurotropic viruses. The company utilizes CRISPR-based technology to create advanced gene-editing medicines aimed at eradicating or disrupting viral genes in patients. By focusing on addressing the medical needs associated with viral infections, Excision aims to advance safe and effective therapeutics that can significantly enhance the quality of life for individuals affected by these diseases globally.

Locanabio

Series B in 2020
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.

SciNeuro

Series A in 2020
SciNeuro Pharmaceuticals develops medicines for patients with central nervous system (CNS) diseases. The company is based in Shanghai, China.

Remix Therapeutics

Series A in 2020
Remix Therapeutics Inc. engages in the biotech research and development business. It discovers and develops various novel therapeutic RNA processing modulators to target various undruggable disease drivers. The company also offers biology platform to identify and prioritize targets with therapeutically-tractable intervention points in RNA processing. Its REMseq platform validates targets and chemical matter discovery and optimization. The company was founded in 2018 and is based in Cambridge, Massachusetts.

Sonoma Pharmaceuticals

Series A in 2020
Sonoma Pharmaceuticals develops and produces stabilized hypochlorous acid (HOCl) products for various healthcare applications, including wound care, animal health, eye care, oral care, and dermatological conditions. The company offers a range of products such as Epicyn, an antimicrobial facial cleanser; Levicyn, a prescription treatment for dermatoses; and Celacyn gel, which promotes healing of scars from surgical procedures and trauma. Additional offerings include SebuDerm for seborrhea management, Ceramax as a skin barrier cream, and Acuicyn for eye-related inflammation and cleanliness. Sonoma's Microcyn product line targets expedited healing of wounds and includes solutions for both human and animal care, addressing conditions such as hot spots and skin irritations. With over 100 commercialized products in 33 countries, Sonoma Pharmaceuticals aims to meet unmet medical needs while enhancing patient care and reducing healthcare costs. The company, originally known as Oculus Innovative Sciences, Inc., was rebranded in December 2016 and is headquartered in Woodstock, Georgia.

Sonoma BioTherapeutics

Series A in 2020
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

Dewpoint Therapeutics

Series B in 2020
Dewpoint Therapeutics, Inc. is a biotech company focused on researching biomolecular condensates and their role in cellular function. Established in 2018 and based in Boston, Massachusetts, the company aims to develop innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women’s health, and virology. Dewpoint Therapeutics utilizes a novel drug platform that specifically targets biomolecular condensates to advance its therapeutic solutions.

Nutcracker Therapeutics

Series B in 2020
Nutcracker Therapeutics, Inc. is a biotechnology company focused on developing mRNA therapeutics using a proprietary microfluidic platform. Established in 2017 and based in Emeryville, California, the company specializes in a fully integrated system that allows for the on-demand production of mRNA therapeutics through its ACORN platform. This innovative, computer-controlled RNA manufacturing system utilizes a nucleic acid sequence to produce optimized, nanoparticle-encapsulated RNA therapeutics on single-use biochips. Nutcracker Therapeutics aims to enhance the scalability and efficiency of mRNA production, enabling healthcare companies to create complex multimodal therapeutics at the point of care. By combining advances in RNA biology with semiconductor manufacturing techniques, the company seeks to streamline the discovery, development, and manufacturing processes for mRNA therapies and vaccines.

Sana Biotechnology

Series A in 2020
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.

Verve Therapeutics

Series A in 2020
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.

Autobahn Therapeutics

Series B in 2020
Autobahn Therapeutics, Inc. develops small molecule therapies for the treatment of central nervous system (CNS) disorders. The company develops ABX-002, a thyroid hormone receptor beta agonist therapy for the treatment of multiple sclerosis (MS), and adrenomyeloneuropathy (AMN). Autobahn Therapeutics, Inc. was formerly known as Llama Therapeutics, Inc. and changed its name to Autobahn Therapeutics, Inc. in December 2019. The company was incorporated in 2017 and is based in San Diego, California.

JW Therapeutics

Series B in 2020
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is relmacabtagene autoleucel, an anti-CD19 CAR-T therapy for relapsed or refractory B-cell lymphoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, China.

ROME Therapeutics

Series A in 2020
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.

Erasca

Series B in 2020
Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations, providing patients with new potential solutions to not just treat but cure cancer. It was founded in 2018 and headquartered in San Diego, California.

Cero Therapeutics

Series A in 2020
CERo Therapeutics, Inc., a biotechnology company, researches and develops platforms for cellular immunotherapy. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Volastra Therapeutics

Seed Round in 2020
Volastra Therapeutics, Inc., a biotechnology company, develops therapies for the treatment of metastatic cancers. The company offers a library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. Volastra Therapeutics, Inc. was incorporated in 2019 and is based in New York, New York.

Sonoma BioTherapeutics

Series A in 2020
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

Boundless Bio

Series A in 2019
Boundless Bio, Inc., biopharma company, develops therapies and medicines for the treatment of cancers. It offers therapeutics based on extrachromosomal DNA (ecDNA) one of the drivers of the aggressive cancers, such as cancers characterized by high copy number amplification of oncogenes. The company was formerly known as Pretzel Therapeutics, Inc. Boundless Bio, Inc. was founded in 2018 and is based in LA Jolla, California.

Encoded Therapeutics

Series C in 2019
Encoded Therapeutics, Inc. is a biotechnology company focused on developing precision gene therapies for severe genetic disorders. The company's innovative platform identifies sequences within the human genome that regulate gene expression through advanced screening and computational methods. Its therapy pipeline targets a variety of genetic and acquired disorders across multiple disease pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular diseases. Founded in 2014 and headquartered in South San Francisco, California, Encoded Therapeutics aims to enhance treatment options available to medical practitioners, ultimately improving patient outcomes and quality of life.

BlackThorn Therapeutics

Series B in 2019
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.

Locanabio

Series A in 2019
Locanabio, Inc., is an RNA-targeting gene therapy company focused on developing therapies for patients with severe neurodegenerative, neuromuscular, and retinal diseases.

Verve Therapeutics

Series A in 2019
Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.

Vividion Therapeutics

Series B in 2019
Vividion Therapeutics, Inc., a biotechnology company, develops therapeutics to treat major unmet medical needs using the platform for proteome-wide small molecule drug discovery. The company combines a proteome-wide small molecule screening approach and synthetic chemistry techniques. It provides small molecule selectivity and creates a path to drugging any protein. The company was incorporated in 2013 and is based in San Diego, California.

Erasca

Series A in 2019
Erasca develops oncology drugs intended to provide precision oncology options. The company's drugs are being developed through multiple discovery programs for undisclosed targets that are biological drivers of cancer and are pursuing additional opportunities for pipeline expansion through academic and biopharmaceutical collaborations, providing patients with new potential solutions to not just treat but cure cancer. It was founded in 2018 and headquartered in San Diego, California.

Maze Therapeutics

Series A in 2019
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.and its also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases.

Transcenta

Venture Round in 2019
Transcenta Holding Ltd. is a clinical-stage biotherapeutics company specializing in the research, development, and manufacturing of antibody-based therapeutics. Founded in 2019 and headquartered in Suzhou, China, Transcenta has additional facilities in major cities including Shanghai, Hangzhou, and Beijing, as well as in Waltham, Massachusetts, and Princeton, New Jersey. The company was formed through the merger of HJB and MabSpace Biosciences and focuses on developing innovative antibodies aimed at treating various conditions. Currently, Transcenta is advancing nine therapeutic antibody molecules targeting oncology and select non-oncology indications, including bone and kidney disorders.

Vir

Series B in 2019
Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, focused on developing therapeutic products to treat and prevent serious infectious diseases. The company employs a combination of innovative technologies and scientific expertise to enhance the immune response against pathogens. Its pipeline includes several product candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir's approach integrates various technology platforms, including antibodies, T cells, and small interfering RNA, to manipulate pathogen-host interactions. The company collaborates with multiple organizations, including the Bill & Melinda Gates Foundation, the National Institutes of Health, and several pharmaceutical companies, to advance its research and development efforts. Additionally, Vir has established agreements for the manufacturing of SARS-CoV-2 antibodies, positioning itself to address emerging infectious diseases. Founded in 2016, Vir Biotechnology aims to make significant advancements in the fight against viral diseases.

Sana Biotechnology

Seed Round in 2019
Sana Biotechnology focuses on creating and delivering engineered cells as medicine for patients. Recent scientific advances make it possible to reprogram cells in the body or replace damaged cells and tissues, creating a new class of medicines to treat a broad array of diseases. The company is a team of scientists, clinicians and biotechnology veterans focused on creating an enduring company that makes meaningful medicines and will change the approach in treating diseases.

Lyell Immunopharma

Series A in 2018
Lyell Immunopharma is focused on advancing the science of T-cell differentiation, functionality, and specificity so that they can develop curative treatments for human diseases. Lyell Immunopharma is headquartered in South San Francisco, California.

KSQ Therapeutics

Series C in 2018
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

OncoResponse

Series B in 2018
OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.

Magnolia Neurosciences

Series A in 2018
Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.

Nohla Therapeutics

Series B in 2018
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

Brii Biosciences

Venture Round in 2018
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.

Nohla Therapeutics

Series B in 2018
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

CStone Pharmaceuticals

Series B in 2018
CStone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative tumor immunotherapy and precision treatment drugs to meet the intensive medical needs of cancer patients in China and around the world.CStone Pharmaceuticals has assembled a world-class management team with extensive experience in new drug development, clinical research, and commercialization. The company has built a rich product pipeline composed of 15 tumor candidate drugs with the combination of tumor immunotherapy as the core.

Metacrine

Series B in 2017
Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Codiak Biosciences

Series C in 2017
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

KSQ Therapeutics

Series B in 2017
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

LifeMine Therapeutics

Series A in 2017
LifeMine Therapeutics, Inc., a biotechnology company, engages in the genomic discovery of new drug modalities from eukaryotic microbes. It utilizes an integrated genomically-enabled drug discovery platform to discover and develop a pipeline of new drugs from fungi. The company was incorporated in 2016 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

Rodeo Therapeutics

Series A in 2017
Rodeo Therapeutics Corp. is a drug development company. The company develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It develops drugs for tissue repair and regeneration. The company was incorporated in 2017 and is based in Seattle, Washington.

Sienna Biopharmaceuticals

Series B in 2017
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Westlake Village, California, focused on developing innovative therapies primarily in immunology and dermatology. The company is advancing several product candidates, including SNA-120, a first-in-class inhibitor targeting tropomyosin receptor kinase A, currently in a Phase IIb trial for psoriasis and related pruritus. Another candidate, SNA-125, is a topical dual Janus kinase 3 inhibitor undergoing Phase I/II trials for atopic dermatitis, psoriasis, and pruritus. Additionally, Sienna is developing SNA-001, a topical suspension of silver particles, which is in pivotal trials for treating acne and reducing the appearance of light-pigmented hair. Sienna Biopharmaceuticals was founded in 2010 as Sienna Labs, Inc. and changed its name in 2016. The company faced financial challenges, filing for Chapter 11 bankruptcy in September 2019, which later converted to Chapter 7.

Vividion Therapeutics

Series A in 2017
Vividion Therapeutics, Inc., a biotechnology company, develops therapeutics to treat major unmet medical needs using the platform for proteome-wide small molecule drug discovery. The company combines a proteome-wide small molecule screening approach and synthetic chemistry techniques. It provides small molecule selectivity and creates a path to drugging any protein. The company was incorporated in 2013 and is based in San Diego, California.

Vir

Venture Round in 2017
Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, focused on developing therapeutic products to treat and prevent serious infectious diseases. The company employs a combination of innovative technologies and scientific expertise to enhance the immune response against pathogens. Its pipeline includes several product candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir's approach integrates various technology platforms, including antibodies, T cells, and small interfering RNA, to manipulate pathogen-host interactions. The company collaborates with multiple organizations, including the Bill & Melinda Gates Foundation, the National Institutes of Health, and several pharmaceutical companies, to advance its research and development efforts. Additionally, Vir has established agreements for the manufacturing of SARS-CoV-2 antibodies, positioning itself to address emerging infectious diseases. Founded in 2016, Vir Biotechnology aims to make significant advancements in the fight against viral diseases.

ApoGen Biotechnologies

Series A in 2016
ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.

Nohla Therapeutics

Series A in 2016
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.

UNITY Biotechnology

Series B in 2016
Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span. The company is focused on creating senolytic medicines that target and eliminate senescent cells, which are associated with various aging-related diseases. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal disorders and Phase Ib trials for knee osteoarthritis; UBX1325, in Phase I trials for diabetic macular edema; and UBX1967, targeting ophthalmologic diseases. Additionally, Unity is exploring therapeutic programs for pulmonary, neurological, kidney, and liver disorders. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. before rebranding in 2015.

BlackThorn Therapeutics

Series A in 2016
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.

Carrick Therapeutics

Series A in 2016
Carrick Therapeutics, Ltd., founded in 2015 and based in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets specific molecular pathways associated with aggressive and resistant cancer forms, allowing for early detection of predictive biomarkers. This approach facilitates timely treatment initiation for patients, enhancing the potential for improved outcomes in cancer care.

Denali Therapeutics

Series B in 2016
Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.

Just - Evotec Biologics

Series A in 2016
Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

Sienna Biopharmaceuticals

Series A in 2016
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Westlake Village, California, focused on developing innovative therapies primarily in immunology and dermatology. The company is advancing several product candidates, including SNA-120, a first-in-class inhibitor targeting tropomyosin receptor kinase A, currently in a Phase IIb trial for psoriasis and related pruritus. Another candidate, SNA-125, is a topical dual Janus kinase 3 inhibitor undergoing Phase I/II trials for atopic dermatitis, psoriasis, and pruritus. Additionally, Sienna is developing SNA-001, a topical suspension of silver particles, which is in pivotal trials for treating acne and reducing the appearance of light-pigmented hair. Sienna Biopharmaceuticals was founded in 2010 as Sienna Labs, Inc. and changed its name in 2016. The company faced financial challenges, filing for Chapter 11 bankruptcy in September 2019, which later converted to Chapter 7.

OncoResponse

Series A in 2016
OncoResponse Inc. is an immuno-oncology company based in Houston, Texas, focused on discovering new cancer immunotherapies and therapeutic antibodies. The company collaborates with MD Anderson Cancer Center to utilize the I-STAR™ platform, which analyzes the human memory B-cell repertoire of patients who have demonstrated exceptional responses to immunotherapy, referred to as "Elite Responders." By studying these patients, OncoResponse aims to harness the human immune system to identify fully human monoclonal antibodies and novel targets. This approach is intended to facilitate the development of innovative antibody-derived therapeutics for cancer treatment.

Sienna Biopharmaceuticals

Series A in 2016
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Westlake Village, California, focused on developing innovative therapies primarily in immunology and dermatology. The company is advancing several product candidates, including SNA-120, a first-in-class inhibitor targeting tropomyosin receptor kinase A, currently in a Phase IIb trial for psoriasis and related pruritus. Another candidate, SNA-125, is a topical dual Janus kinase 3 inhibitor undergoing Phase I/II trials for atopic dermatitis, psoriasis, and pruritus. Additionally, Sienna is developing SNA-001, a topical suspension of silver particles, which is in pivotal trials for treating acne and reducing the appearance of light-pigmented hair. Sienna Biopharmaceuticals was founded in 2010 as Sienna Labs, Inc. and changed its name in 2016. The company faced financial challenges, filing for Chapter 11 bankruptcy in September 2019, which later converted to Chapter 7.

Codiak Biosciences

Series B in 2016
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Lodo Therapeutics

Series A in 2016
Lodo Therapeutics Corporation is a drug discovery and development company dedicated to creating novel therapeutics derived from natural sources to address significant health challenges, particularly resistant infectious diseases and cancers. Founded to advance the scientific vision of Dr. Sean Brady from Rockefeller University, Lodo utilizes a genome-based, culture-independent platform to discover and characterize small molecules from microbial sources found in soil. By leveraging advancements in DNA sequencing and bioinformatics, the company aims to unlock the therapeutic potential of previously undiscovered molecules encoded in microbial DNA, with a focus on treating conditions that have high unmet medical needs. Lodo Therapeutics, supported by Accelerator Corporation, is headquartered in New York City, where its laboratory and offices are located within the Alexandria Center for Life Science.

Petra Pharma

Series A in 2016
Petra Pharma Corporation, a pharmaceutical company, discovers and develops therapies that modulate phosphoinositide (PI) signaling pathways for the treatment of cancer and other serious diseases. It focuses on novel enzyme targets that play a central role in various important cellular processes, including cell division, growth, trafficking, and signaling. The company was incorporated in 2015 and is based in New York, New York.

Codiak Biosciences

Series A in 2015
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

Just - Evotec Biologics

Series A in 2015
Just Evotec Biologics was founded in 2014 and acquired by Evotec in 2019. The company has an intense focus on the design of innovative and integrated technologies to accelerate the development of biotherapeutics and reduce their manufacturing cost. Core strengths include antibody discovery, molecular design, process and product design and manufacturing plant design.

Metacrine

Series A in 2015
Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Pulmatrix

Post in 2015
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.

Denali Therapeutics

Series A in 2015
Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.

Semma Therapeutics

Series A in 2015
Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, aiming to provide alternatives to insulin injections. The company emerged from research by Professor Douglas Melton, which led to the discovery of a method for generating billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics, which is now dedicated to creating a cell-based therapy that combines these proprietary cells with advanced devices to effectively replace the missing beta cells in diabetic patients without the need for immunosuppression. Established in 2014 and headquartered in Cambridge, Massachusetts, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is committed to bringing its novel therapeutic solutions to clinical settings, ultimately enhancing the quality of life for individuals living with diabetes.

Kura Oncology

Venture Round in 2015
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company’s lead product candidate is Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, and other hematologic malignancies. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

UNITY Biotechnology

Series A in 2015
Unity Biotechnology, Inc. is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span. The company is focused on creating senolytic medicines that target and eliminate senescent cells, which are associated with various aging-related diseases. Its lead drug candidates include UBX0101, currently in Phase II clinical trials for musculoskeletal disorders and Phase Ib trials for knee osteoarthritis; UBX1325, in Phase I trials for diabetic macular edema; and UBX1967, targeting ophthalmologic diseases. Additionally, Unity is exploring therapeutic programs for pulmonary, neurological, kidney, and liver disorders. Founded in 2009 and headquartered in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. before rebranding in 2015.

Syros Pharmaceuticals

Series B in 2014
Syros Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for cancer and genetic disorders through innovative gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing a Phase II clinical trial for specific patient subsets with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in a Phase I clinical trial for select advanced solid tumors. Syros employs a unique approach that integrates gene regulatory circuit mapping and modulation of gene expression factors, supported by a proprietary platform of assay technologies and bioinformatics. The company collaborates with Incyte Corporation to discover therapeutic targets, particularly for myeloproliferative neoplasms, and has a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. Founded in 2011 and headquartered in Cambridge, Massachusetts, Syros Pharmaceuticals was previously known as LS22, Inc. and rebranded in 2012.

VentiRx Pharmaceuticals

Series B in 2014
VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops and commercializes Toll-like Receptor 8 (TLR8) immunotherapies for the treatment of cancer, respiratory, and inflammatory diseases. It provides Motolimod, a lead investigational drug to mobilize a patient's own immune system by directly activating myeloid dendritic cells, monocytes, and natural killer cells to fight cancer. VentiRx Pharmaceuticals, Inc. was founded in 2006 and is based in Seattle, Washington. As of February 28, 2017, VentiRx Pharmaceuticals, Inc. operates as a subsidiary of Celgene Corporation.

Sorbent Therapeutics

Series D in 2014
Sorbent Therapeutics, Inc. develops treatment for end stage renal disease patients undergoing dialysis. The company develops fluid retaining polymers for therapeutic uses, such as treatment of kidney diseases. Sorbent Therapeutics, Inc. was founded in 2005 and is based in Vernon Hills, Illinois.

SAGE Therapeutics

Series C in 2014
SAGE Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative treatments for central nervous system (CNS) disorders. Its lead product, ZULRESSO, is an intravenous formulation of brexanolone designed for postpartum depression. The company's pipeline includes SAGE-217, a neuroactive steroid in Phase III trials for various depressive disorders and anxiety, and SAGE-324, currently in Phase II trials for essential tremors and previously tested for other neurological conditions. Additionally, SAGE-718, which targets multiple CNS disorders, has completed Phase I trials, while SAGE-904 and SAGE-689 are in early clinical stages for NMDA-related disorders. SAGE Therapeutics has formed strategic collaborations with Shionogi & Co., Ltd. and Biogen Inc. for the development and commercialization of its key product candidates. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company aims to address the unmet needs of patients affected by debilitating CNS disorders through scientific innovation and strategic partnerships.

Bellerophon Therapeutics

Series A in 2013
Bellerophon Therapeutics LLC is a clinical stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitric oxide delivery device, INOpulse®, and are in Phase 2 clinical trials – one for the treatment of PAH and a second for the treatment of PH-COPD. The company's third product candidate, bioabsorbable cardiac matrix (BCM), is an injectable device currently undergoing a feasibility clinical trial, which is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in U.S. drug development, for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (heart attack).

SAGE Therapeutics

Series B in 2013
SAGE Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative treatments for central nervous system (CNS) disorders. Its lead product, ZULRESSO, is an intravenous formulation of brexanolone designed for postpartum depression. The company's pipeline includes SAGE-217, a neuroactive steroid in Phase III trials for various depressive disorders and anxiety, and SAGE-324, currently in Phase II trials for essential tremors and previously tested for other neurological conditions. Additionally, SAGE-718, which targets multiple CNS disorders, has completed Phase I trials, while SAGE-904 and SAGE-689 are in early clinical stages for NMDA-related disorders. SAGE Therapeutics has formed strategic collaborations with Shionogi & Co., Ltd. and Biogen Inc. for the development and commercialization of its key product candidates. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company aims to address the unmet needs of patients affected by debilitating CNS disorders through scientific innovation and strategic partnerships.

Syros Pharmaceuticals

Series A in 2013
Syros Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for cancer and genetic disorders through innovative gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing a Phase II clinical trial for specific patient subsets with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in a Phase I clinical trial for select advanced solid tumors. Syros employs a unique approach that integrates gene regulatory circuit mapping and modulation of gene expression factors, supported by a proprietary platform of assay technologies and bioinformatics. The company collaborates with Incyte Corporation to discover therapeutic targets, particularly for myeloproliferative neoplasms, and has a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. Founded in 2011 and headquartered in Cambridge, Massachusetts, Syros Pharmaceuticals was previously known as LS22, Inc. and rebranded in 2012.

Sorbent Therapeutics

Venture Round in 2013
Sorbent Therapeutics, Inc. develops treatment for end stage renal disease patients undergoing dialysis. The company develops fluid retaining polymers for therapeutic uses, such as treatment of kidney diseases. Sorbent Therapeutics, Inc. was founded in 2005 and is based in Vernon Hills, Illinois.

TRELYS

Seed Round in 2013
Trelys, Inc. operates in the biotechnology sector. The company was incorporated in 2012 and is based in San Francisco, California.

Receptos

Series B in 2013
Receptos is a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing best- and first-in-class drugs.

Theraclone Sciences

Series B in 2013
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.

Sorbent Therapeutics

Series C in 2012
Sorbent Therapeutics, Inc. develops treatment for end stage renal disease patients undergoing dialysis. The company develops fluid retaining polymers for therapeutic uses, such as treatment of kidney diseases. Sorbent Therapeutics, Inc. was founded in 2005 and is based in Vernon Hills, Illinois.

Receptos

Venture Round in 2012
Receptos is a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing best- and first-in-class drugs.

Permeon Biologics

Venture Round in 2011
Permeon Biologics is focused on improving human health through its innovative Intraphilin Technology Platform. This platform identifies naturally occurring human proteins known for their ability to enhance cellular uptake and permeate cell membranes effectively. By leveraging these "supercharged proteins," Permeon Biologics aims to develop a new generation of therapeutic drugs that can deliver functional proteins capable of replacing or restoring defective cellular pathways associated with various diseases. This approach represents a significant advancement in the field of intracellular biologics, positioning the company at the forefront of therapeutic innovation.

Groove Biopharma

Series B in 2011
Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.

Agios Pharmaceuticals

Series C in 2011
Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of therapies targeting cellular metabolism, particularly in cancer and rare genetic disorders. The company offers TIBSOVO, an oral targeted inhibitor approved for treating relapsed or refractory acute myeloid leukemia (AML) and newly diagnosed AML, as well as IDHIFA, which targets AML patients with specific genetic mutations. Agios is advancing multiple clinical programs, including TIBSOVO for frontline AML and cholangiocarcinoma, and developing mitapivat for pyruvate kinase deficiency and thalassemia. Other investigational compounds include vorasidenib for solid tumors and AG-270 for specific cancer types. Agios employs a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for successful early clinical proof of concept and accelerated approvals. The company was originally established in 2007 under the name Cancer Metabolism Therapeutics before rebranding to Agios Pharmaceuticals in 2008.

Theraclone Sciences

Venture Round in 2011
Theraclone Sciences, Inc. is a Seattle-based discovery-stage biotechnology company focused on developing novel therapeutic antibodies for the treatment of cancer and infectious diseases. The company utilizes its In-Situ Therapeutic Antibody Rescue technology to rapidly test human antibodies, identifying those with exceptional biological functions. Notable among its offerings is TCN-032, a recombinant human monoclonal antibody aimed at treating patients hospitalized with severe influenza. Theraclone’s antibody programs are in varying stages of preclinical and clinical development, targeting significant unmet medical needs such as triple negative and endocrine treatment-resistant HER-2 negative breast cancer, infectious disease-associated cancers, and multidrug-resistant bacteria. Theraclone was founded in 2004 and was formerly known as Spaltudaq Corporation, changing its name in March 2009. The company is privately held and has received venture funding from several investment firms.

Kythera Biopharmaceuticals

Series D in 2011
KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California. KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Pulmatrix

Series B in 2011
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.